|1.||Palmer, Robert H: 19 articles (01/2015 - 11/2008)|
|2.||Higuchi, Hisashi: 12 articles (04/2010 - 09/2003)|
|3.||Yoshida, Keizo: 11 articles (07/2015 - 09/2003)|
|4.||Clauw, Daniel J: 11 articles (01/2014 - 10/2005)|
|5.||Gendreau, R Michael: 11 articles (06/2013 - 10/2005)|
|6.||Arnold, Lesley M: 9 articles (01/2015 - 06/2010)|
|7.||Mease, Philip J: 9 articles (06/2014 - 10/2005)|
|8.||Takahashi, Hitoshi: 9 articles (01/2009 - 09/2003)|
|9.||Kamata, Mitsuhiro: 8 articles (03/2010 - 10/2003)|
|10.||Wang, Yong: 7 articles (06/2014 - 11/2008)|
09/01/2004 - "Results of this study show milnacipran to be beneficial in patients with chronic pain. "
01/01/2015 - " doses of milnacipran provided moderate levels of pain relief (at least 30% pain intensity reduction) to about 40% of participants treated, compared to 30% with placebo, giving a number needed to treat for an additional beneficial outcome (NNT) of 6 to 10 (high quality evidence). "
07/01/2012 - "The highest responder rates were found in patients with greater than four-point improvement in BDI scores (milnacipran vs. placebo: pain, 57.5% vs. 39.0%; PGIC, 60.1% vs. 38.2%; 2-measure composite, 49.0% vs. 27.9%; all p < 0.01), although significant differences between treatment groups were also found in patients with no improvement or worsening of depressive symptoms. "
03/01/2010 - "Treatment with milnacipran resulted in a significant improvement of chronic pain in the orofacial region irrespective of concurrent symptoms of depression. "
11/01/2008 - "Compared with placebo, significantly greater proportions of milnacipran-treated patients were FM composite responders (100 mg/d: P = 0.01; 200 mg/d: P = 0.02) and FM pain composite responders (100 mg/d: P = 0.03; 200 mg/d: P = 0.004). "
02/01/2008 - "Further studies are needed to evaluate the safety and efficacy of milnacipran, determine optimal dosing, confirm if beneficial effects are sustained, and clarify the drug's role relative to, and in conjunction with, other treatments for fibromyalgia."
01/01/2010 - "In adults, milnacipran was generally effective in the treatment of fibromyalgia in four well designed trials of 3 or 6 months' duration. "
01/01/2013 - "To investigate whether milnacipran is safe and effective in improving cognitive function in patients with fibromyalgia. "
01/01/2013 - "Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial."
08/01/2010 - "The clinical safety and efficacy of milnacipran 100 and 200 mg/day in individuals with fibromyalgia has been investigated in four large, randomized, double-blind, placebo-controlled studies and three long-term extension studies. "
|3.||Neuralgia (Stump Neuralgia)
10/01/2012 - "In many animal studies, intrathecal administration of milnacipran is effective in neuropathic pain management. "
05/01/2005 - "Milnacipran might be effective for suppression of neuropathic pain."
01/01/2015 - "There was no evidence to support the use of milnacipran to treat neuropathic pain conditions."
01/01/2015 - "We included randomised, double-blind studies of eight weeks' duration or longer, comparing milnacipran with placebo or another active treatment in chronic neuropathic pain. "
01/01/2015 - "To assess the analgesic efficacy and associated adverse events of milnacipran for chronic neuropathic pain in adults. "
|4.||Major Depressive Disorder (Major Depressive Disorders)
05/01/2000 - "This study demonstrates that milnacipran is effective with good tolerability in preventing recurrence in major depressive disorder over 1 year in patients with recurrent depression who responded to acute treatment with milnacipran and continued their response for 18 weeks."
11/01/2009 - "The antidepressant efficacy of milnacipran has been clearly established in a number of randomized, double-blind, placebo-controlled clinical trials, and it has been widely used for treating major depressive disorder. "
06/01/2013 - "In the present study, we investigated both 5-HTT and NET occupancies by PET using radioligands [(11)C]DASB and (S,S)-[(18)F]FMeNER-D(2), in six patients, each with major depressive disorder (MDD), using various doses of milnacipran. "
04/01/2010 - "In a milnacipran study, ninety-six patients with major depressive disorder were treated with milnacipran, 50-100 mg/day, for 6 weeks. "
09/01/2013 - "Pierre Fabre and Forest Laboratories are developing levomilnacipran extended release (ER) [FETZIMA™], an enantiomer of milnacipran, for the treatment of major depressive disorder (MDD). "
01/01/2010 - "Other domains assessed during the milnacipran trials include fatigue, multidimensional functioning, mood, sleep quality, and patient-reported dyscognition. "
01/01/2010 - "Milnacipran has proven efficacy in managing global FMS symptoms and pain as well as improving symptoms of fatigue and cognitive dysfunction without affecting sleep. "
05/01/2013 - "Milnacipran has been found to be beneficial for treating some troublesome fibromyalgia-associated symptoms, including fatigue and cognitive dysfunction."
05/01/2013 - "Studies show that milnacipran may be effective for fibromyalgia-associated symptoms including depression and fatigue. "
06/01/2014 - "Fibromyalgia patients in the milnacipran studies had high levels of baseline fatigue. "
|1.||Serotonin (5 Hydroxytryptamine)
|8.||Antidepressive Agents (Antidepressants)
|2.||Drug Therapy (Chemotherapy)